The FDA approved on 6/21/2018 the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to... read more
The FDA approved on 6/21/2018 the Eversense Continuous Glucose Monitoring (CGM) system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to... read more
Autolus Therapeutics plc (“Autolus”) announced on 6/22/2018 the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530... read more
Phelps Hospital has launched Dascena’s InSight algorithm house wide. InSight is a machine learning platform built for accurate sepsis onset predictions using only vital signs in the hospital’s EHR... read more
Servier and Taiho Pharmaceutical Co., Ltd. Announced on 6/21/2-18 clinical data from the pivotal Phase III trial (TAGS) for Lonsurf (trifluridine and tipiracil, TAS-102) which showed... read more
... read more
The vast majority of the laws are directed towards pharmacy benefits managers (PBMs). Most prohibit PBMs from placing limits on... read more
iTeos Therapeutics SA announced on 6/20/2018 the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors... read more
Genedrive plc announced on 6/20/2018 its receipt of a multi-partner grant award from the UK National Institute for Health Research’s Invention for Innovation programme, for the development and... read more
OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("... read more
Caladrius Biosciences, Inc. (Nasdaq:CLBS) announced on 6/19/2018 that the U.S. Food and Drug Administration (“FDA”) has granted regenerative medicine... read more
Crown Bioscience announced on 6/19/2018 that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.
... read more
Like everyone, people with type 2 diabetes and obesity suffer from depression and anxiety, but even more so. Researchers at Joslin Diabetes Center now have demonstrated a surprising potential... read more
Translate Bio announced on 6/18/2018 that it has launched an initial public offering of 7,700,000 shares of its common stock. In addition, Translate Bio expects to grant the underwriters a 30-day... read more
Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics announced today a collaboration to investigate interventions targeting gastrointestinal (GI) metabolites that may cause... read more
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) announced on 6/14/2018 that it has initiated dosing in its phase 1 clinical trial of TTI-622 (SIRPaFc-IgG4), a checkpoint inhibitor of the... read more
